The dual PI3K/mToR inhibitor omipalisib/GSK2126458 inhibits clonogenic growth in oncogenically-transformed cells from neurocutaneous melanocytosis Journal Article


Authors: Basu, D.; Salgado, C. M.; Bauer, B.; Khakoo, Y.; Patel, J. R.; Hoehl, R. M.; Bertolini, D. M.; Zabec, J.; Brzozowski, M. R.; Reyes-Múgica, M.
Article Title: The dual PI3K/mToR inhibitor omipalisib/GSK2126458 inhibits clonogenic growth in oncogenically-transformed cells from neurocutaneous melanocytosis
Abstract: Background: Omipalisib has been found to affect the viability of cancer cells. However, its effect on clonogenicity – a feature of cancer stem cells, is not clear. Cells isolated from neurocutaneous melanocytosis (NCM) patients’lesions grow clonogenically. The aim of this study was to investigate the effect of omipalisib treatment on clonogenic growth of NCM cells in vitro. Materials and Methods: Clonogenic growth efficiency was evaluated by colony formation assays with or without specific growth factors. Activation of MEK and Akt was determined by immunoblots. Colony formation and cell viability were assessed upon pharmacological inhibition of MEK, Akt and mToR. Results: Clonogenicity appeared to depend on bFGF and IGF1signaling through ERK and Akt. Omipalisib treatment prevented colony formation and induced autophagic cell death. Conclusion: Signaling through Akt is important for survival of clonogenic cells in NCM, and omipalisib treatment as a monotherapy or in combination with MEK162 could be an effective therapeutic strategy to inhibit clonogenic growth. © 2018 International Institute of Anticancer Research. All Rights Reserved.
Keywords: neurocutaneous melanocytosis; omipalisib; clonogenicity; mek162
Journal Title: Cancer Genomics and Proteomics
Volume: 15
Issue: 4
ISSN: 1109-6535
Publisher: The International Institute of Anticancer Research  
Date Published: 2018-07-01
Start Page: 239
End Page: 248
Language: English
DOI: 10.21873/cgp.20082
PROVIDER: scopus
PUBMED: 29976629
PMCID: PMC6070711
DOI/URL:
Notes: Article -- Export Date: 1 August 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Yasmin Khakoo
    149 Khakoo